atl1103 anti cancer medications, page-82

on about the cap raise they had mainly

Mark Diamond, managing director, said ?this funding will enable us to conduct additional studies of ATL1103 which we believe will add significant value to the drug and strongly enhance its commercial potential.?

The first human trial of ATL1103, the company?s drug designed to block growth hormone receptor expression, is being developed for diseases where reducing growth hormone and insulin growth factor 1 (IGF?I) effects may lead to disease treatment.

The placement?s proceeds will allow Antisense to conduct the multiple dose stage of the study that will follow on from the single ascending dose stage.


>>> old report but this part of interest to me =?
________________________________________________________

In another interesting development for the company, these placement proceeds will also allow Antisense to conduct its planned experimental program to evaluate the potential of ATL1103 in cancer prevention and therapy.

_________________________________________________________


REF http://www.marketstock.com.au/?p=35766